Copper-to-Zinc Ratio as an Inflammatory Marker in Serum of Iraqi Patients with Axial Spondyloarthritis

Mohammed S. Al-Hindawi1,2, Abdulnasser M. Al-Gebori1, and Mohammed Hadi Munshed Alosami2 DOI. 10.21931/RB/2023.08.02.56

1 Applied Sciences Department, Applied Chemists Division, University of Technology, Baghdad, Iraq.
2 Department of Medicine, Rheumatology Unit, Colleges of Medicine, University of Baghdad, Baghdad, Iraq.

Corresponding author: Mohammed.S.AlHindawi@utechnology.edu.iq.

Abstract: Axial spondyloarthritis (axSpA) is a chronic rheumatic inflammatory disease affecting mainly the spine and sacroiliac joints. Since the copper-to-zinc ratio (Cu/Zn) indicates an inflammatory response, the change in ratio is expected to correlate with axSpA. This study compared levels of Cu/Zn in the serum of axSpA patients. Serum samples were obtained from 53 patients with axSpA divided according to biological treatment into cohorts A and B, and 28 healthy control as cohort C. Serum levels of Cu and Zn were determined first by a fully automated chemistry analyzer TC-Matrix Plus, then the ratio was obtained. The elevated serum Cu concentration means of cohort B (189.32 ± 13.808 µg/dL) compared to cohort A (168.85 ± 7.244 µg/dL) and cohort C (155.68 ± 3.707 µg/dL) with 0.029 p-values. Reduced Zn concentration means of cohort B (79.74 ± 4.344 µg/dL) compared to cohort A (91.26 ± 4.159 µg/dL) and cohort C (100.93 ± 6.161 µg/dL) with 0.031 p-values. The Cu/Zn mean of cohort B was (2.54 ± 0.25) compared to the Cu/Zn mean of cohort A (1.968 ± 0.125) and cohort C (1.679 ± 0.104) with 0.002 p-values. Due to the results suggesting that the differences between cohorts were associated with inflammatory responses since there was a similar change in ESR levels; however, the differences between cohorts A and B are due to the anti-inflammatory therapy (TNF inhibitor) that cohort A was treated with.

Key words: Axial spondyloarthritis, copper-to-zinc ratio, copper, zinc, inflammation.

Introduction

Axial spondyloarthritis (axSpA) is a chronic rheumatic inflammatory disease with many symptoms affecting mainly the spine and sacroiliac joints (SU)1. The axSpA refers to both patients who have structural damage that can be seen on radiographs that knows as radiographic axial spondyloarthritis or ankylosing spondylitis (AS) and patients who do not appear a structural damage on radiographs that knows as non-radiographic axial spondyloarthritis (nr-axSpA)2. The disorder of axSpA has been linked to extra-articular manifestations (EAMs) like inflammatory bowel disease (IBD), psoriasis, and anterior uveitis3.

Copper (Cu) is an essential trace element that serves as a biocatalyst in human metabolism. It catalyzes the oxidation of ascorbic acid and oils and affects protein synthesis, tissue regeneration, bone formation, ATP production, hemoglobin synthesis, and nerve and muscle impulse transmission4,5. Zinc (Zn) is an essential dietary component for the body linked to cancer risk. It requires the production and activation of several enzymes, catalyzes their actions, and has a role in preserving a healthy immune system, DNA synthesis, protein synthesis, and cell division6,7. In addition to calcium, Zn is one of two metals that bind to a leukocyte protein called calprotectin, the main biomarker of IBD that can develop in axSpA patients and is associated with disease activity8,9.

The serum copper-to-zinc ratio (Cu/Zn) level is one of the characteristics linked to a lower ability to maintain or reestablish homeostasis following a destabilizing event. In older people, an increase in this ratio above 2.0 generally indicates an inflammatory response or a reduction in nutritional Zn status10.

This study will focus on the changes in Cu, Zn, and Cu/Zn effects and their association with an inflammatory response in patients with axSpA. Also, the correlation with some biochemical and inflammatory parameters.

Materials and methods

Patients and healthy control groups

The study comprised patients with axSpA, and about eighty-one serum samples were collected at Baghdad Teaching Hospital between October 24, 2021, and January 24, 2022, and divided into three cohorts. The trial’s entry criteria for cohort A were that patients were previously diagnosed with axSpA according to the Assessment of Spondyloarthritides International Society (ASAS) and had been treated with a tumor necrosis factor (TNF) inhibitor. Thirty-four patients, with an age mean of 37.09 ± 1.381 years, were in this cohort. Cohort B trial entry criteria involved patients with axSpA who had not yet been treated with a TNF inhibitor; nineteen patients, with an age mean of 36.11 ± 1.138 years, were in this cohort. In cohort C, there were twenty-eight healthy control individuals with an age mean of 36.11 ± 1.138 years. The demographic information from cohorts, including gender, age, body mass index (BMI), and smoking, is in Table 1.
Patients' assessment

Patients had a clinical examination at the hospital. A complete blood count, renal function tests (blood urea nitrogen and serum creatinine), liver function tests (serum alanine transaminase and aspartate transaminase), and erythrocyte sedimentation rate (ESR) were among the tests performed at the lab. Also, the genetic risk factor for axSpA, human leukocyte antigen B27 (HLA-B27), was assessed for all samples. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to measure disease activity and functional status. The TC-Matrix Plus (Teco Diagnostics company, USA), an automated chemical analyzer, was used for Zn and Cu concentration measurements.

Statistical analysis

The Statistical Package for Social Sciences version 26 (SPSS-v26) program evaluated the results. Parametric data are supplied as means ± standard error mean (SEM), while Non-parametric data are presented as median using two independent samples tests, and the values are in median (IQR). Statistical analysis of serum Zn and Cu levels between axSpA patients and the healthy control group were compared using the independent samples t-test. Statistical analysis of serum Zn and Cu levels and the other tests that changed among cohorts was compared using the one-way ANOVA and Scheffe tests for post hoc multiple comparisons. Pearson's coefficients were used to perform correlation analysis, and it was based on variable distribution. At a p-value <0.05, the differences were deemed statistically significant.

Results

Patient characteristics

Fifty-three patients with axSpA, thirty-four patients were on TNF inhibitor treatment (cohort A, 10 females, mean age = 37.09 ± 1.381 years, mean BMI = 27.673 ± 0.556 kg/m²), nineteen patients that had no treated with TNF inhibitor (cohort B, one female, mean age = 36.11 ± 1.597 years, mean BMI = 26.822 ± 0.793 kg/m²) and twenty-eight healthy control (cohort C, 5 females, mean age = 36.11 ± 1.138 years, mean BMI = 25.604 ± 0.509 kg/m²) were a part of the research. Twenty-six patients (49%) had BASDAI of less than four, and the mean of cohorts A and B was (3.191 ± 0.355) and (5.674 ± 0.414) respectively, with a p-value <0.001. All cohorts A and B patients had positive HLA-B27 (100%). The patient population's baseline features are shown in Table 2.

General laboratory tests

Cohort A: ESR mean = 18.03 ± 2.642 mm/hour, hemoglobin (Hb) mean = 13.183 ± 0.294 g/dL, glutamate oxaloacetate aminotransferase (GOT) mean = 21.946 ± 1.7 U/L, glutamate pyruvate aminotransferase (GPT) mean = 27.742 ± 2.645 U/L, urea mean = 26.037 ± 1.285 mg/dL, creatinine mean = 1.275 ± 0.509 mg/dL.

Cohort B: ESR mean = 34.37 ± 5.552 mm/hour, Hb mean = 13.451 ± 0.345 g/dL, GOT mean = 21.946 ± 1.7 U/L, GPT mean = 27.742 ± 2.645 U/L, urea mean = 26.037 ± 1.285 mg/dL, creatinine mean = 1.275 ± 0.509 mg/dL.

Cohort C: ESR mean = 11.46 ± 0.94 mm/hour, Hb mean = 13.183 ± 0.294 g/dL, GOT mean = 21.946 ± 1.7 U/L, GPT mean = 27.742 ± 2.645 U/L, urea mean = 26.037 ± 1.285 mg/dL, creatinine mean = 1.275 ± 0.509 mg/dL.

Table 1. Demographic information from cohorts.
3.943 ± 0.165 g/dL, GOT mean = 21.429 ± 1.222 U/L, GPT mean = 24.571 ± 0.987 U/L, urea mean = 25.893 ± 1.28 mg/dL, creatinine mean = 0.757 ± 0.03 mg/dL.

The mean difference among the cohorts and the p-value from the one-way ANOVA test are shown in Table 3.

The multiple comparisons between cohorts of the ESR test show a highly significant increase between cohort B and the other cohorts shown in Table 4.

Serum copper and zinc levels in patients with axSpA

The results show that there is an increase in Cu levels in axSpA patients [176.19 ± 6.847 µg/dL] compared to the healthy control group [155.68 ± 3.707 µg/dL, p=0.04], and there is a decrease in Zn levels in axSpA patients [87.13 ± 3.158 µg/dL] compared to the healthy control group [100.93 ± 6.161 µg/dL, p=0.03].

Serum copper and zinc levels change with therapy

The results show that there is an increase in Cu levels in cohort B patients that did not have bio treatment [189.32 ± 13.808 µg/dL] compared to cohort A patients that had bio treatment [168.85 ± 7.244 µg/dL]. The cohort C healthy control group [155.68 ± 3.707 µg/dL, p=0.029] and there is a decrease in Zn levels in axSpA patients [79.74 ± 4.344 µg/dL] compared to the healthy control group [100.93 ± 6.161 µg/dL, p=0.031].

The multiple comparisons between cohorts of the Cu and Zn test show a significant increase in Cu levels and a significant decrease in Zn levels between cohort B and the other cohorts shown in Table 5.

Serum copper to zinc ratio in patients with axSpA

The Cu/Zn shows an increase in the ratio mean of patients [2.173 ± 0.125] compared to the ratio mean of the healthy control group [1.679 ± 0.104, p=0.007].

Serum copper-to-zinc ratio changes with therapy

The Cu/Zn shows that there is an increase in the ratio mean of cohort B [2.54 ± 0.25] compared to the ratio mean of cohort A [1.968 ± 0.125] and the ratio mean of cohort C [1.679 ± 0.104, p=0.002].

Correlation of serum copper to zinc ratio

Table 6 shows a positive correlation between Cu/Zn and Cu with ESR. In addition, a significant negative correlation of Cu/Zn and a positive correlation of Zn were observed with Hb. However, a non-significant negative correlation between Cu and Zn has been shown, Zn has a non-significant negative correlation with ESR, and Cu has a non-significant positive correlation with Hb.

Discussion

Compared to the healthy control group, serum Cu concentrations were higher in axSpA patients, and serum Zn concentrations were lower in axSpA patients, specifically in cohort B patients that did not have biotreatment. This, therefore, led to increased Cu/Zn.

The newness or novelty of this research is represented by the determining levels of these trace elements and their ratio in this disease, which considers observation that leads to a new knowledge discovery in the relationship between these trace elements and their ratio in this disease for the first time in Iraqi patients. However, many limitations can be identified. The involvement of females in the study sample was shallow because axSpA is a male sexual disorder, with males having nine times the frequency of women; therefore, we could not compare with gender. Also, there were no patients with negative HLA-B27, so we could not make a comparison on this parameter.

As far as we know, there have been very few studies on the changes of Cu and Zn in axSpA patients, so the discussion of the results will be focused on the roles of these parameters in inflammation, as axSpA is an inflammatory disorder, and will be compared to another rheumatic disease like rheumatoid arthritis (RA).

Inflammation causes Cu metabolism to be altered, increasing serum Cu levels, as has been concluded in previous studies. Cu is required for immunological respon-
se, including the creation of interleukin-2 (IL-2) by activated lymphocytic cells, and it enhances cellular and humoral immunity by influencing T lymphocytes. More than 70% of serum Cu is linked to glycoprotein ceruloplasmin (Cp) that is upregulated by pro-inflammatory cytokines TNF in the liver. The increased serum Cu concentration is most likely due to a Cp elevation. Cu pro-inflammatory effect is due to its ability to cause oxidative stress by catalyzing the production of reactive oxygen species (ROS) via many reactions or by lowering glutathione levels, a powerful cellular antioxidant. The pathophysiology of AS is complicated by oxidative stress components induced by neutrophil activation. The serum Cu concentration results of the study agreed with a study that performed an analysis on AS and RA that confirmed the presence of an elevated serum Cu level in this disorders.

Zn deficiency assimilation can cause an increase in the inflammatory state, immune system changes, extracellular matrix breakdown, a decrease in polymorphonuclear cell phagocytic activity, and Zn-mediated disruption of the T_{H1}/T_{H2} balance with an increase in T_{H1}. That leads to increased IL-17 production, which has been reported as one of the elevated parameters in axSpA patients. Inflammation can be induced by altered cytokine synthesis during Zn deficiency, such as IL-1 release. Furthermore, a comparison of circulating cytokines and Zn status revealed that lower Zn levels may have been associated with higher levels of IL-6, IL-8, and TNF.

In inflammatory diseases, some processes decrease serum Zn concentrations and raise serum Cu concentrations. A typical symptom of these disorders is raised Cu/Zn. The Cu/Zn ratio results agree with a study confirming that the Cu/Zn appears clinically significant as an inflammatory-nutritional indicator. Increases in Cu/Zn may be related to age, and the link between Cu/Zn and mortality in the elderly might be due to the factors that cause Cu/Zn to rise, such as chronic low-level inflammation, poor nutritional status, and particular underlying conditions such as cardiovascular disease (CVD). The parameters correlated with each other in axSpA patients. They showed that ESR was positively correlated with serum Cu/Zn (r = 0.331, p = 0.015), and these results agreed with the study of Malavolta (M). A comparison between axSpA patients that had been treated or had not been treated with a TNF inhibitor showed a significant difference in arthritis disease activity as assessed by BASDAI towards the group that had not been treated with a TNF inhibitor. Patients with axSpA showed high levels of Cu and low levels of Zn, especially in the non-TNF inhibitor group, which led to an increase in Cu/Zn ratios, suggesting that the differences between cohorts were due to inflammatory responses since there was a similar change in ESR levels. However, cohorts A and B differ due to the anti-inflammatory therapy (TNF inhibitor) with which cohort A was treated.

**Conclusions**

A comparison between axSpA patients that had been treated or had not been treated with a TNF inhibitor showed a significant difference in arthritis disease activity as assessed by BASDAI towards the group that had not been treated with a TNF inhibitor. Patients with axSpA showed high levels of Cu and low levels of Zn, especially in the non-TNF inhibitor group, which led to an increase in Cu/Zn ratios, suggesting that the differences between cohorts were due to inflammatory responses since there was a similar change in ESR levels. However, cohorts A and B differ due to the anti-inflammatory therapy (TNF inhibitor) with which cohort A was treated.

**Bibliographic references**

Table 5. Multiple comparisons for Cu and Zn between the different groups (Scheffe-test).

Table 6. Correlation of Cu/Zn with ESR and Hb in axSpA patients.


